Bill Drew Maddux, MD Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1107 Highway 395, Gardnerville, NV 89410 Phone: 775-783-3081 Fax: 775-782-1513 |
News Archive
Elizabeth Kurylo, communications manager with the International Trachoma Initiative, describes the International Coalition for Trachoma Control's plan "to eliminate blinding trachoma, one of the seven neglected tropical diseases targeted by END7, ... called 2020 INSight: The End in Sight," in this post on the Global Network for Neglected Tropical Diseases' "End the Neglect" blog.
Oncolytics Biotech Inc. announced today that the Cancer Therapy Research Center at the University of Texas Health Science Center (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with metastatic melanoma.
According to MassDevice.com, the online business journal of the medical device industry, medical device approval times under the Food & Drug Administration's 510(k) clearance process jumped 30 percent between 2005 and 2008. MassDevice's exclusive investigation of 10 years of FDA data, Eye on the FDA: H1 2009, shows that approval times for medical devices increased nearly 2 percent — while the number of 510(k) applications declined more than 19 percent — even as the FDA's budgets and staff levels rose.
Scientists at The Scripps Research Institute (TSRI) have found that resveratrol, the red-wine ingredient once touted as an elixir of youth, powerfully activates an evolutionarily ancient stress response in human cells.
› Verified 6 days ago